Table 2.

Trial outcomes and results of dose comparisons

	DA60	DA90	OR/HR and CI	P
CR	75%	73%	1.07 (0.83-1.39)	.6
CRi	9%	8%
CR/CRi	84%	81%	1.21 (0.90-1.63)	.2
Induction death	4%	6%	1.63 (0.97-2.73)	.07
Resistant disease	12%	13%	1.04 (0.74-1.47)	.8
CR/CRi post–course 1	66%	68%	0.89 (0.70-1.14)	.4
30-day mortality	4%	6%	1.56 (0.94-2.61)	.09
60-day mortality	5%	10%	1.98 (1.30-3.02)	.001
2-year OS	60%	59%	1.16 (0.95-1.43)	.15
2-year RFS	48%	51%	1.05 (0.85-1.30)	.7
2-year cumulative incidence of relapse	43%	39%	1.00 (0.79-1.27)	1.0
2-year cumulative incidence of death in CR	8%	10%	1.27 (0.79-2.04)	.3
2-year OS from CR	69%	70%	1.04 (0.79-1.38)	.8
2-year OS censored at SCT	60%	60%	1.20 (0.96-1.51)	.11

RFS, relapse-free survival; SCT, stem cell transplant.